Zealand Pharma gets highest price target to date after positive analysis by major US bank
For the second day in a row, analysts at Goldman Sachs raise their price target for the shares of the Danish biotech company Zealand Pharma.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.